This page is intended as reference information for the general public.
What is COMIRNATY Omicron XBB.1.5 and what is it used for?
COMIRNATY Omicron XBB.1.5 is a vaccine that has been developed by BioNTech and Pfizer. This vaccine has been adapted to target the Omicron XBB.1.5 COVID-19 variant.
COMIRNATY Omicron XBB.1.5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 12 years of age and older.
COMIRNATY Omicron XBB.1.5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in children aged 5 to 11 years.
COMIRNATY Omicron XBB.1.5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in infants and children aged 6 months to 4 years.
The vaccine causes the immune system (the body's natural defences) to produce antibodies and blood cells that work against the virus, so giving protection against COVID-19.
As COMIRNATY Omicron XBB.1.5 does not contain the virus to produce immunity, it cannot give you COVID-19.
Reporting Side Effects
As with any new medicine in the UK, this product will be closely monitored to allow quick identification of new safety information. You can help by reporting any side effects that you may get. To report any side effects that you may get, please refer to the information at the bottom of this page.
The information provided on this site is intended for general information and education for UK based members of the public and is not intended to be a substitute for advice provided by a doctor or other qualified healthcare professional.
Medicines in Northern Ireland fall under the remit of the European Medicines Agency (EMA) whilst medicines in Great Britain (England, Scotland and Wales) fall under the remit of the Medicines and Healthcare products Regulatory Agency (MHRA) following the UK leaving the European Union. These agencies are responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies.
If you would like to see the Summary of Product Characteristics (SPC) or Patient Information Leaflet (PIL) for COMIRNATY please follow these links:
COMIRNATY Omicron XBB.1.5
COMIRNATY Omicron XBB.1.5
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://coronavirus-yellowcard.mhra.gov.uk for how to report side effects.
Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professional for specific, health-related advice and support.
If you are concerned about a side-effect it can be reported directly via the Coronavirus Yellow Card reporting site https://coronavirus-yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. When completing a report please include the vaccine brand and batch/lot number if available.